Bluejay Diagnostics (BJDX) Shares Surge on Strategic Argonaut Partnership

Shares of Bluejay Diagnostics (BJDX) surged on Tuesday, June 2, 2026, after the company announced a strategic partnership with contract manufacturer Argonaut to scale production of its Symphony diagnostic platform. The stock leapt as much as 42% in intraday trading, its steepest single-day climb in six months. The deal aims to accelerate U.S. commercialization of Bluejay’s point-of-care tests, including CE-marked COVID-19 and sepsis assays. Argonaut will take over manufacturing and supply chain logistics, a move the company said will reduce time to market and improve gross margins. Bluejay’s CEO noted the collaboration removes a critical bottleneck and positions the firm to meet rising demand. Financial terms were not disclosed.